ondansetron has been researched along with Carcinoma, Anaplastic in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 9.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 5.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verwimp-Hoeks, MPA | 1 |
| van Herpen, CML | 1 |
| Burger, DM | 1 |
| Fraschini, G | 1 |
| Ciociola, A | 1 |
| Esparza, L | 1 |
| Templeton, D | 1 |
| Holmes, FA | 1 |
| Walters, RS | 1 |
| Hortobagyi, GN | 1 |
1 trial available for ondansetron and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
1 other study available for ondansetron and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
Topics: Adult; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Carcinoma; Chemoradiot | 2012 |